Skip To Main Content
Marc Palobart on Muck Rack

Marc Palobart

As seen in: BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marc

Contact Marc, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells

|
By Carles A. Foguet, Josep Tarrago-Celada, Miriam Tarrado-Castellarnau, Marc Palobart
| BioRxiv
Abstract Therapeutic resistance in cancer emerges from genetic or epigenetic mechanisms that enable cell survival under drug pressure. While several resistance mechanisms to cyclin-dependent kinase inhibitors have been identified, acquired resistance is still a therapeutic challenge. Here, we have systematically analyzed metabolic reprogramming in colorectal cancer cells exposed to Palbociclib, a CDK4/6 inhibitor, or Telaglenestat, a glutaminase inhibitor.
Open in Who Shared Issue with article?
See all 1 articles